Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
W. Wuyts (Leuven, Belgium), F. Bonella (Essen, Germany), N. Chaudhuri (Manchester, United Kingdom), F. Varone (Roma, Italy), D. Antin-Ozerkis (New Haven, CT, United States), H. Mueller (Biberach, Germany), C. Coeck (Brussels, Belgium), K. Rohr (Ingelheim am Rhein, Germany), V. Cottin (Lyon, France)
Source: International Congress 2022 – Promising new approaches in idiopathic interstitial pneumonias
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Wuyts (Leuven, Belgium), F. Bonella (Essen, Germany), N. Chaudhuri (Manchester, United Kingdom), F. Varone (Roma, Italy), D. Antin-Ozerkis (New Haven, CT, United States), H. Mueller (Biberach, Germany), C. Coeck (Brussels, Belgium), K. Rohr (Ingelheim am Rhein, Germany), V. Cottin (Lyon, France). Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON. 1935
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|